Omada Health Announces GLP-1 Flex Care, Giving Employers a New, Flexible Path to Support Obesity Care

Core Insights - Omada Health has launched GLP-1 Flex Care, a new offering designed to help employers provide access to GLP-1 medications for obesity while managing costs effectively [1][2][3] Group 1: Offering Details - GLP-1 Flex Care connects employees with anti-obesity medication, virtual care, and lifestyle support, allowing members to purchase medications independently through cash-pay channels [1][3] - The program includes clinical evaluation, prescribing, ongoing medical guidance, and oversight, ensuring that employees receive necessary support throughout their GLP-1 journey [3][4] - Members can receive evaluations for GLP-1 eligibility, lab orders, and prescriptions for FDA-approved medications, along with ongoing clinical oversight and lifestyle counseling [3][4] Group 2: Market Demand and Challenges - There is a growing demand for GLP-1 medications among employees, but many employers find full coverage economically challenging [2][4] - Employers are seeking financially sustainable ways to manage GLP-1 coverage while ensuring employees have access to effective treatment options [2][5] - Fragmented cash-pay channels currently lack coordinated medical oversight, leading to concerns about clinical best practices and sustainable outcomes [2][5] Group 3: Effectiveness and Outcomes - Omada's GLP-1 care track has shown strong real-world results, with 67% of members persisting on medication after one year, compared to 47-49% in comparable studies [4] - Members who continued their GLP-1 medication achieved an average weight loss of 18.4% after one year, significantly higher than the 11.9% seen in similar real-world evidence [4][5] - Research indicates that pairing GLP-1 medication with Omada's wraparound care model leads to longer medication adherence and better weight loss outcomes [5] Group 4: Employer Engagement - GLP-1 Flex Care is designed to support diverse employer benefit strategies, catering to various coverage approaches for GLP-1 medications [5][6] - Omada has already supported over 150,000 members on GLP-1s, indicating a strong market presence and commitment to flexible, evidence-based solutions [5][8] - The offering will be available to employers starting later in 2026, providing a timely option for those looking to enhance their employee health benefits [7]